Senseonics Holdings, INC

Senseonics Holdings, Inc. announced the closing of asset purchase agreements for its Eversense CGM activities in Germany, Spain, Sweden, and Italy.

Senseonics Holdings, Inc. stockholders approved an amendment to increase authorized common stock from 70 million to 140 million shares, effective May 20, 2026.

Senseonics Holdings, Inc. announced first quarter 2026 financial results, showcasing an 87% year-over-year revenue increase to $11.7 million and raising its full-year revenue guidance.

Senseonics Holdings, Inc. has amended its loan agreement, potentially accessing up to $140 million in senior secured term loans, with initial tranches expected to close May 6, 2026.

Senseonics Holdings, Inc. finalized agreements to acquire commercial Eversense CGM assets in key European territories, aiming to expand direct operations.

Senseonics Holdings, Inc. announced robust fourth quarter and full year 2025 financial results, driven by significant revenue growth and strategic commercialization efforts.

Senseonics Holdings, Inc. has entered into a definitive agreement to acquire certain German assets from Ascensia Diabetes Care Deutschland GmbH, marking a significant step in its European commercialization strategy.

Senseonics Holdings, Inc. reported a significant revenue increase in Q3 2025, driven by U.S. sales and 365-day product demand, even as management acknowledges substantial doubt about its ability to continue as a going concern.

Senseonics Holdings, Inc. reports significant revenue growth and improved gross margins in Q2 2025, bolstered by recent capital raises that alleviate going concern doubts.

Senseonics Holdings, Inc. reports increased revenue for Q1 2025 but acknowledges substantial doubt about its ability to continue as a going concern without additional funding.

Senseonics Holdings reported a net loss for Q3 2024 and acknowledged substantial doubt about its ability to continue as a going concern due to ongoing losses and the need for additional funding.

Senseonics Holdings, Inc. reported a revenue increase in Q2 2024, but also experienced a net loss due to higher operating expenses and other factors.

Senseonics Holdings, Inc. reports increased revenue and gross profit for 2025, driven by the Eversense 365 launch and regaining commercialization rights from Ascensia, despite ongoing net losses and liquidity concerns.

Senseonics Holdings, Inc. files its 10-K report for the year ended December 31, 2024, detailing its financial performance and strategic advancements in the global commercialization of its Eversense CGM systems.

Senseonics Holdings, Inc. released its 2023 annual report, detailing financial performance and strategic advancements in its glucose monitoring technology.

Steven Edelman, a Director at Senseonics Holdings, Inc., received 2,402 shares of common stock valued at $5.36 per share as compensation for his services.

Senseonics Holdings reports insider Francine Kaufman sold 4,010 shares of common stock on June 15, 2026, to cover tax obligations upon vesting of restricted stock units.

Mukul Jain, Chief Operating Officer of Senseonics Holdings, Inc., reported a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Senseonics Holdings, Inc. Chief Financial Officer, Frederick T. Sullivan, reported a transaction involving the sale of common stock.

Kenneth L. Horton of Senseonics Holdings, Inc. reported a transaction involving the sale of common stock.

Senseonics Holdings, Inc. reports a Form 4 filing detailing a transaction by Director Brian B. Hansen.

Senseonics Holdings, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, executive compensation votes, and a proposed increase in authorized shares.

Senseonics Holdings, Inc. is seeking stockholder approval for a reverse stock split ranging from 1-for-10 to 1-for-20 to maintain its NYSE American listing and improve stock marketability.

Senseonics Holdings, Inc. has filed a definitive proxy statement with the SEC.

Senseonics Holdings will hold its annual stockholders meeting virtually on May 21, 2025, to elect directors, approve executive compensation, and ratify the appointment of KPMG LLP as its independent auditor.

Senseonics announced strong early launch indicators for its Eversense 365 CGM system, including record new patient shipments and increased prescriber engagement.

Senseonics Holdings is asking shareholders to approve a reverse stock split in the range of 1-for-25 to 1-for-50 to potentially increase its stock price and maintain its NYSE American listing.

Robert J. Smith, through Energy Capital, LLC and Plato & Associates, LLC, has reported a beneficial ownership of 6.14% in Senseonics Holdings, Inc. common stock.